99 related articles for article (PubMed ID: 31128178)
1. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
[TBL] [Abstract][Full Text] [Related]
2. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
[TBL] [Abstract][Full Text] [Related]
3. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
[TBL] [Abstract][Full Text] [Related]
4. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
[TBL] [Abstract][Full Text] [Related]
5. Structural analysis of the human fibroblast growth factor receptor 4 kinase.
Lesca E; Lammens A; Huber R; Augustin M
J Mol Biol; 2014 Nov; 426(22):3744-3756. PubMed ID: 25219510
[TBL] [Abstract][Full Text] [Related]
6. The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.
Georgoulia PS; Todde G; Bjelic S; Friedman R
Biochim Biophys Acta Gen Subj; 2019 Apr; 1863(4):732-741. PubMed ID: 30684523
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance.
Dehghanian F; Alavi S
Sci Rep; 2021 Aug; 11(1):16593. PubMed ID: 34400727
[TBL] [Abstract][Full Text] [Related]
8. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
9. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
[TBL] [Abstract][Full Text] [Related]
10. Structural study of ponatinib in inhibiting SRC kinase.
Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
[TBL] [Abstract][Full Text] [Related]
11. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
15. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
16. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.
Huang Z; Tan L; Wang H; Liu Y; Blais S; Deng J; Neubert TA; Gray NS; Li X; Mohammadi M
ACS Chem Biol; 2015 Jan; 10(1):299-309. PubMed ID: 25317566
[TBL] [Abstract][Full Text] [Related]
17. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
18. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
[TBL] [Abstract][Full Text] [Related]
19. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Yang B; Zhang H; Wang H
J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
